Tumor necrosis factor (TNF) alpha inhibitors are widely used to treat inflammatory bowel disease (IBD) and Sweet syndrome is known as an extra-intestinal cutaneous manifestation of IBD. We wish to highlight a paradoxical case and successful management of anti-TNF-agent-induced Sweet syndrome compared with Sweet syndrome treated by anti-TNF agents.